|  | TyG index | |||
---|---|---|---|---|---|
Characteristics | Total | Q1 | Q2 | Q3 | Q4 |
4.78–6.89 | 6.90–7.31 | 7.32–7.80 | 7.81–11.38 | ||
Subjects (n) | 19,345 | 4,861 | 4,859 | 4,812 | 4,813 |
TyG index | 7.36 ± 0.68 | 6.54 ± 0.27 | 7.10 ± 0.12 | 7.54 ± 0.14 | 8.26 ± 0.42 |
Age, years | 60.1 ± 12.9 | 58.1 ± 13.9 | 60.6 ± 12.9 | 60.6 ± 12.3 | 61.3 ± 12.2 |
Male, n (%) | 7738 (40.0) | 1780 (36.6) | 1971 (40.6) | 1935 (40.2) | 2052 (42.6) |
Systolic BP, mmHg | 139 ± 21 | 136 ± 21 | 139 ± 20 | 140 ± 20 | 142 ± 20 |
Diastolic BP, mmHg | 76 ± 11 | 75 ± 12 | 76 ± 11 | 77 ± 11 | 77 ± 11 |
FBG, mmol/L | 6.79 ± 3.18 | 5.35 ± 0.97 | 5.96 ± 1.41 | 6.72 ± 2.19 | 9.16 ± 4.94 |
TC, mg/dL | 208.4 ± 42.0 | 197.0 ± 39.8 | 207.4 ± 40.9 | 212.4 ± 41.1 | 217.2 ± 43.5 |
LDL-c, mg/dL | 124.7 ± 37.4 | 119.6 ± 35.5 | 128.3 ± 37.2 | 128.5 ± 37.3 | 122.4 ± 38.9 |
HDL-c, mg/dL | 52.6 ± 14.6 | 61.0 ± 15.7 | 53.9 ± 14.0 | 49.5 ± 12.1 | 46.0 ± 11.7 |
TG, mg/dL | 124.0 (88.6-179.8) | 743.5 (60.2–88.6) | 115.1 (98.3–132.0) | 160.3 (127.5-189.5) | 221.4 (159.4-292.3) |
Dyslipidemia, n (%) | 9099 (47.0) | 1930 (39.7) | 2273 (46.8) | 2446 (50.8) | 2450 (50.9) |
Diabetes Mellitus, n (%) | 6524(33.7) | 559 (11.5) | 1138 (23.4) | 1816 (37.7) | 3011 (62.6) |
Hypertension, n (%) | 11,809 (61.0) | 2591 (53.3) | 2974 (61.2) | 3037 (63.1) | 3207 (66.6) |
Chronic kidney disease, n (%) | 2930 (15.2) | 543 (11.2) | 730 (15.0) | 744 (15.5) | 913 (19.0) |
Anti-hypertensive drugs, n (%) | 3834 (19.8) | 755 (15.5) | 990 (20.4) | 1011 (21.0) | 1078 (22.4) |
Lipid-lowering drugs, n (%) | 1586 (8.2) | 303 (6.2) | 373 (7.7) | 419 (8.7) | 491 (10.2) |
Diabetes drugs, n (%) | 995 (5.1) | 110 (2.3) | 194 (4.0) | 246 (5.1) | 445 (9.3) |
Antiplatelets, n (%) | 814 (4.2) | 159 (3.3) | 191 (3.9) | 216 (4.5) | 248 (5.2) |